NOTES TO CONSOLIDATED  FINANCIAL STATEMENTS in the accounts receivables. No servicing asset or liability has been recorded as the Company’s compensation for servicing the assets is just adequate to cover the cost of its servicing responsibilities. The Company receives annual servicing fees approximating one percent of the outstanding balance and rights to future cash flows arising after the investors in the securitization trust have received their contractual return. The investors and the securitization trust have no recourse to the Company’s other assets for failure of debtors to pay when due. The Company’s residual interests are subordinate to the investors’ interests. The Facilities expire in December 2003 and are renewable for one-year periods at the Company’s option. Sales of receivables under these programs result in a reduction of accounts receivable on the Company’s Consolidated Balance Sheets. Residual interests are carried at their fair value estimated as the net realizable value, which considers the relatively short liquidation period and includes an estimated provision for credit losses, and are included in Other Current Assets. Pursuant to the terms of the Facilities, the Company had sold approximately $82.7 million and  $42.1 million of trade accounts receivable as of December 31, 2002 and 2001, respectively, resulting in a reduction of trade accounts receivable on the Company’s Consolidated Balance Sheets, and received funding of approximately  $67.1 million and $37.2 million. In 2002, proceeds from new sales totaled $474.1 million and cash collections totaled $455.2 million. In 2001, proceeds from new sales totaled $411.6 million and cash collections totaled $406.4 million. Costs associated with the sale of receivables, primarily related to the discount and loss on sale, were $1.6 million,  $1.4 million and $0.4 million in 2002, 2001 and 2000, respec- tively, and are included in Other (Income) Expense, net. Other intangible assets subject to amortization consisted of the following: On January 1, 2002, the Company adopted Statement of Financial Accounting Standards (SFAS) No. 142, “Goodwill and Other Intangible Assets,” whereby goodwill is no longer amortized, but instead is subject to a periodic impairment review. As the Company’s operations are comprised of one reporting unit, the Company reviews the recoverability of its goodwill by comparing the Company’s fair value to the net book value of its assets. If the book value of the Company’s assets exceeds the Company’s fair value, the goodwill is written down to its implied fair value. Pursuant to SFAS No. 142, the results for periods prior to adoption are not to be restated. If SFAS No. 142 had been effective January 1, 2000, net loss and earnings per basic and diluted share would have been as follows (in millions, except per share information): S64 Edwards Lifesciences Corporation Note 6. GOODWILL AND OTHER INTANGIBLE ASSETS Years Ended December 31,  2001 2000 Reported net income (loss) $ (11.4) $ (271.7) Goodwill amortization, net of tax 17.7 28.3 Adjusted net income (loss) $ 6.3 $ (243.4) Earnings per basic share: Reported net loss $ (0.19) — Adjusted net income $ 0.11 — Earnings per diluted share: Reported net loss $ (0.19) — Adjusted net income $ 0.10 — Unpatented December 31, 2002 (in millions) Patents Technology Other Total Cost $ 96.8 $ 36.3 $ 5.8 $ 138.9 Accumulated amortization (58.2) (15.5) (3.3) (77.0) Net carrying value $ 38.6 $ 20.8 $ 2.5 $ 61.9 Unpatented December 31, 2001 (in millions) Patents Technology Other Total Cost $ 128.8 $ 39.8 $ 5.1 $ 173.7 Accumulated amortization (84.9) (16.4) (3.8) (105.1) Net carrying value $ 43.9 $ 23.4 $ 1.3 $ 68.6